Alzheimer natna atana Aduhelm (Aducanumab) chungchanga hriat tur awmte

Kan hmangaih tak, nu emaw, pa emaw, a nih loh leh kan ṭhian emaw pawhin Alzheimer natna a vei a, chu chuan hriatrengna a tichhe thei a, kan lungngaihna leh ṭanpui theih lohna chu thuin a sawi thei lo. Khawvel hmun hrang hranga Doctor leh Scientist-te chuan he natna damdawi zawngin nasa takin hma an la mek a ni. Chutiang hmalakna avang chuan khawvel chuan damdawi Aducanumab , brand name Aduhelm hmanga siam chungchang hi an sawi tan ta a ni. Mahse he damdawi hi beiseina lian tak awm mah se, inhnialna nasa tak a awm bawk. Tunah chuan he damdawi siamchhuah hi tihtawp a ni ta. Chuvangin vawiinah hian he Aduhelm hi eng nge a nih, engtin nge a hnathawh, engvangin nge a awm tawh loh tih hi han sawi ila.

A awlsam zawngin sawi ila, he Aduhelm (Aducanumab) hi eng nge ni?

Aduhelm hi Alzheimer natna hmasa ber, chu chu hriatna lama harsatna nei lo damlote hnena pek thin damdawi a ni . Damdawi chi hrang hrang monoclonal antibodies an tih zingah a tel a ni .

Ngaihtuah teh, Alzheimer natna a lo awm chuan kan thluaka nerve cells inkarah protein chi khat amyloid an tih chu a lo awm khawm a, bawlhhlawh ang maiin a inkhung khawm a ni. Hei hi amyloid plaques kan ti a . Heng plaque te hian thluak cell te a tichhia a, an thih tir thin. Aduhelm damdawi hnathawh ber chu thluaka amyloid plaque awmkhawmte hriatchhuah a, taksain a paih chhuah theihna tura puih a ni.

He damdawi hi US FDA chuan thil danglam deuhin a pawm a, agency ngei advisory board rawtna chu ngaihthah a ni. Chumi avang chuan damdawi lam mithiam thenkhat chuan he damdawi hi a him leh that loh chungchangah zirchianna tam zawk neih a ngai tih an zawtfiah a ni.

Mahse, he damdawi siamtu company hian kum 2024 khan an siam chhuak vek tawh lo a, a chhan chu a hnuah kan la hmu ang.

He damdawi hian taksaah engtin nge hna a thawh?

Hei hi thla khatah vawi khat IV infusion hmanga pek thin damdawi a ni . Kan sawi tawh ang khan Alzheimer natna lan chhuah dan ber pakhat chu thluaka protein amyloid-beta an tih chu a khawlkhawm a, plaques a siam a ni. Hei hian thluak cell te a thi a, chu chu hriatrengna hloh leh nungchang inthlak danglamna thlentu ber a ni.

Aduhelm ruihhlo hian detective bik angin hna a thawk a. Thluak chhungah a lut a, chu amyloid plaques awmna hmun dik tak chu a hre chiang hle. Anmahni chu a hre chiang a, a nghet tlat a ni. Tichuan kan taksa ngeia immune system hnenah signal a thawn a, "Hetah hian thil pakhat lak chhuah ngai a awm," a ti a. Tichuan immune system cells te chu an rawn lut a, chu plaques te chu an tichhia ta a ni.

Scientist-te chuan hetianga plaque tihbo a nih chuan thluak cell-te chu an thi tawh lo ang a, hriatrengna leh ngaihtuahna thiamna a chhe zual zel chu a thunun thei ang tih an ngaihtuah a.

He damdawi hi a hlawk tak tak em? Engvangin nge chutiang thil chungchangah chuan inhnialna a awm?

Hei hi mi tam takin zawhna an neih chu a ni. Aduhelm damdawi hman tangkai dan zirchian nan hian zirchianna lian tak pahnih neih a ni.

1. Zirchianna hmasa ber: Hei hian damdawi Aduhelm hian thluaka amyloid plaques awm zat a ti tlem tih a tarlang. Tin, damdawi dose sang tak ei thinte hriatrengna leh nitin hna thawh theihna tlahniam rate pawh a ti hniam deuh bawk. Mahse damdawi chuan natna chu a titawp thei lo va, a tidanglam thei lo bawk.

2. Zirna pahnihna: He zirchianna hian damlote tan hlawkna a nei lo. Chuvangin he zirchianna hi a laiah tihtawp a ni ta a ni.

Chu zirchianna pakhat result chauh chu FDA advisory board lungawina tur a tling lo. Mahse FDA chuan he damdawi hi pawmpui turin thutlukna a siam ta a ni. Mahse chutih rual chuan he damdawi siamtu company Biogen chu kum 9 chhung hun a pe a, he damdawi hi a thatzia finfiah nan zirchianna dang nei turin a pe bawk. He pawmpuina nghal hian sawiselna nasa tak a siam a, damdawi in system lian thenkhat chuan damdawi chungchanga hriat belh a nih hma chuan an damlote hnena pek loh an rel ta a ni.

Aducanumab leh Lecanemab inthlauhna

Aducanumab (Aduhelm) nena inang damdawi dang Lecanemab (Leqembi) tih a awm bawk. Tin, monoclonal antibody a ni bawk. Heng pahnih hian thluaka amyloid proteins te chu target-in hna an thawk a ni. Mahse, an hnathawh danah hian danglamna tlem a awm. Chu chu heng damdawi pahnih hian amyloid plaque siamna kawngah hian stage hrang hrang pahnih ah hna an thawk tihna a ni. Lecanemab hian kum 2023 khan FDA phalna a hmu a, zirchianna atanga a lan dan chuan natna zual zel hi 20%-30% velin a ti hniam thei a ni.

Aducanumab hian eng side effect nge a neih?

Damdawi dang ang bawkin Aducanumab hian side effect a nei thei a ni . Chung zinga ṭhenkhat chu thil pawi tak a ni thei a, chuvangin fimkhur a pawimawh hle.

A pawimawh ber chu hetiang damdawi ei mi tu emaw hian natna lan chhuah dan danglam tak a neih chuan a doctor hnenah a hriattir nghal tur a ni.

Chuti a nih chuan engvangin nge he damdawi hi tihtawp a nih?

Kum 2024 January thla khan Biogen chuan Aducanumab siam leh hralh chu an titawp vek dawn tih an puang. Mi tam tak chuan hei hi himna ngaihtuah vang emaw, a that loh vang emaw niin an ngai. Mahse chu chu a chhan tak tak a ni lo.

Company chuan he hmalakna hi an resources (sum leh pai, research team, etc.) te chu Alzheimer damdawi dang, a bik takin Lecanemab ang damdawi siam leh tihlarna atana an hman a tum vang a nih thu an sawifiah a ni. Chu chu, hei hi sumdawnna leh resource management chungchanga thutlukna a ni a, damdawi him leh that loh ngaihtuah avanga thutlukna siam a ni lo tihna a ni.

He thutlukna siam a nih chuan November 1, 2024 hnuah chuan damlo, prescription-a he damdawi dawng tawhte pawhin an hmu thei tawh dawn lo.